INTRODUCTION
B-cell non Hodgkin lymphomas (B-NHLs) represent a heterogeneous group of disorders characterized in most cases by distinct chromosomal translocations involving the immunoglobulin (IG) genes. 1 However, these translocations are not sufficient for tumor formation, and other genetic abnormalities including concurrent deregulation of other dominant oncogenes and/or inactivation of tumor suppressor genes (TSGs) are necessary for lymphoma development. 2, 3 Physical mapping of chromosome deletions in tumor cells has facilitated the identification of classical TSGs such as P16 INK4a , ATM, P53, and RB, by demonstrating mutation of the remaining alleles. 4 These genes elicit a recessive phenotype and encode proteins that affect several cellular pathways, such as those controlling proliferation, apoptosis, differentiation and genomic integrity.
However, in many other common regions of genomic loss, no TSG carrying biallelic inactivation has been yet identified, indicating that the "two-hit" requirement may not always be necessary for tumorigenesis. Indeed, mutation of a single allele of P27 and P53 is sufficient to promote tumor formation in mice. 5, 6 These haplo-insufficient tumor suppressors retain a functional unmutated allele and promote tumorigenesis through reduced gene dosage and subsequently reduced protein levels.
In an initial study using conventional comparative genomic hybridization (CGH) analysis, we reported the presence of a putative tumor suppressor gene locus at the short arm of chromosome 8 (8p) in mantle cell lymphoma. 7 Subsequent studies have confirmed that this deletion is not only common in mantle cell lymphoma but also in other B-cell malignancies. [8] [9] [10] Chromosome 8p is also one of the most common sites of deletion in epithelial tumors. [11] [12] [13] [14] [15] [16] [17] This genomic loss has been repeatedly associated with tumor progression and advanced or metastatic disease. 7, 9, 11, 17 However, although various potential TSGs have been identified across chromosome 8p, none
For personal use only. at PENN STATE UNIVERSITY on March 1, 2013. bloodjournal.hematologylibrary.org From fulfills Knudson´s criteria (presence of biallelic mutation) in a significant portion of tumors. [12] [13] [14] [15] [16] 18, 19 These findings indicate that this chromosome arm may harbor one or more haploinsufficient tumor suppressor genes. 20, 21 In contrast to carcinomas and sarcomas, a detailed search for a common region of deletion across 8p has not been yet performed in B-NHL. In this report, we delineated a common region of deletion of ∼600 kb in 8p21.3 in various B-NHL subtypes. In vitro assays suggest that TRAIL-R1
and TRAIL-R2 may be the target of the deletion and act as dosage-dependent tumor suppressor genes by impairing the TRAIL-apoptotic pathway.
For personal use only. at PENN STATE UNIVERSITY on March 1, 2013. bloodjournal.hematologylibrary.org From
MATERIAL AND METHODS
Tumor specimens. To screen for deletions of chromosome 8p, forty-five B-cell lymphoma cell lines were studied with genome-wide CGH to BAC microarrays (array CGH): Granta 519, HBL2, SP49, Z138, REC1, NCEB1, JVM2, UPN1 and UPN2 (mantle cell lymphoma); OZ, VAL, Karpas 422, DOHH2, Karpas 353, PR1, OCI-LY8, Karpas 231, SUDHL6, ROS50, RL, SCI1, BEVA and Granta 452 (diffuse large B-cell lymphoma with t(14;18)(q32;q21)); CTB1, MD901, MD903, RIVA, RCK8 and CIPULLO (diffuse large B-cell lymphoma lacking t(14;18)); ELIJAH, NAB2, PL29018, SERAPHINA, Wien133, P32, BALM9, BL41, CA46, Namalwa and KHM10B (Burkitt lymphoma), SSK41 and Karpas 1718 (marginal zone lymphoma); Karpas 1106 (primary mediastinal B-cell lymphoma), JVM13 (B-cell prolymphocytic leukemia) and GASH (hairy cell leukemia). References for their derivation can be checked in a recently published manuscript. 22 In addition, lymph-node and/or bone marrow samples from 22 patients with B-NHL (9 mantle cell lymphoma, 4 follicle center lymphoma, 4 diffuse large B cell lymphoma, 3 Burkitt lymphoma, 2 splenic marginal zone lymphoma), and 3 peripheral blood samples from patients with B-cell chronic lymphocytic leukemia (B-CLL), all with suspected 8p deletion as documented by previous cytogenetic or conventional CGH analyses, were also studied. Additional lymph node specimens from 30 patients with B-NHL and 50 peripheral blood or bone marrow samples from patients with B-CLL were studied with FISH using the BAC RP11-89M8 that maps to the MDR. For mutational analyses, an independent series of 117 lymph node samples from untreated patients with different B-NHL subtypes was also studied. For this study, approval was obtained from the University of Valencia and the University of Navarra institutional review boards. Informed consent was provided according to the Declaration of Helsinki.
Molecular cytogenetic analyses.
Cell lines with chromosome 8p alterations were studied by Gbanding and color cytogenetics using reported methods. 7 To validate the results of array CGH, For personal use only. at PENN STATE UNIVERSITY on March 1, 2013. bloodjournal.hematologylibrary.org From cell lines and selected patients with 8p deletion were analyzed with FISH using ten BAC and PAC clones mapped across 8p but not included in the array: RP4-605G11 in 8p23.3, CTB-877B12 (8p23.2), GS1-877E9 (8p23.1), GS1-265M2 (8p23.1), GS1-148G17 (8p22), GS1-389E9 (8p21.2), GS1-72M22 (8p21.1), GS1-398G7 (8p12), RP5-826O12 (8p11.22) and GS1-392C11 (8p11.21).
Clones were obtained from the Institute for Molecular Biotechnology (Jena, Germany). To delineate the deleted interval further, additional fifteen BAC clones mapped to 8p21 were also studied by FISH in cell lines with the smallest interval of deletion (RP11-110I16, RP11-67H12, RP11-420B22, RP11-233H21, RP11-677P13, RP11-382J24, RP11-582J16, CTD-2238J6, RP11-459E5, RP11-89M8, CTD-3188H20, RP11-177H13, RP11-204M16, RP11-288N10, RP11-158F9); these were obtained from the CHORI (Oakland, CA, USA) and from Research Genetics (Invitrogen Corp., Huntsville, AL, USA). The centromere-specific chromosome 8 probe (CEP 8, Vysis) was co-hybridized in dual-color FISH experiments. BAC/PAC clones were cultured following standard procedures; DNA was purified and labeled with SpectrumGreen-dUTP or SpectrumOrange-dUTP (Vysis). FISH results were analyzed using the 'QUIPS Imaging Software' from Vysis or the ISIS software from MetaSystems (Altlusheim, Germany).
Parallel genomic and gene expression microarray analyses. An array-CGH microchip with 2,460 BAC and P1 clones over the genome (HumArray versions 1.4 and 2.0), which includes 69 clones mapped to chromosome 8p, was applied as reported. 23, 24 After normalization of individual array-CGH experiments, mean log2 ratios (tumoral DNA vs. control DNA) were plotted and the resultant graphs were converted to the log2 domain. The observed log2 ratios were excluded from further analysis if there were fewer than two replicate spots (out of 3) or if the standard deviation of the replicates was above 0.2. The clones that were present in fewer than 50% of the samples were also removed from the dataset. Genomic losses were defined when log2 ratios were lower than -0.5 for hemizygosity, and lower than -1.4 for homozygous deletion. To initially investigate the expression of the genes mapped across 8p, the "Lymphochip" cDNA microarrays were and TRAIL-R4 were designed in the 5' untranslated region CpG island of the published sequences near translation start site (Supplemental Table A (http://fokker.wi.mit.edu/primer3/) using sequences masked by REPEATMASKER. For the first PCR 100 ng genomic DNA, 10 pmol of each primer and Taq polymerase (Qiagen, Germany) were used. PCR products were sequenced using primers for the second PCR and Big Dye Terminator Cycle Sequencing kit v3.0 (Applied Biosystems, USA). Sequencing reactions were electrophoresed on ABI3700 automated sequencers. Base calling was performed using PHRED. 28, 29 Trace files were assembled, inspected visually and edited in GAP4. 30 TRAIL sensitivity assays. Cell lines were cultured according to standard conditions. As a positive control, the Jurkat cell line (DSMZ collection, Germany), which is sensitive to TRAILinduced apoptosis, was also included in the study. Exponentially growing cells were plated at 1x10 6 (Table 1 and Figure 1C) . Results of array CGH were independently confirmed by applying FISH with probes mapping to 8p that were not included into the array, but also using clones from the array ( Figure 1D ). At this level of resolution all deletions were heterozygous.
To delineate the deletion further, BAC/PAC clones covering the 1.5 Mb deleted area were firstly mapped to cell lines with the smallest deletions using FISH, narrowing the commonly deleted interval down to ~0.6 Mb. The MDR extended from BACs RP11-382J24 and RP11-109B10 at telomeric and centromeric boundaries, respectively. Notably, one mantle cell lymphoma cell line (Z138) exhibited a monoallelic deletion of 650 kb, which included TRAIL-R1 gene just at the Table D ). Mutations were also excluded in two putative TSGs mapped to 8p21, deleted in breast cancer 2 (DBC2) and PPP3CC. In these, several polymorphisms were identified, which are shown in Supplemental Table D. In addition, the interval of genomic loss in 8p21.3 in Z138 cell line, consisting of 650kb of genomic DNA, which was the shortest deletion ranging from BAC RP11-177H13 to BAC CTD-2036J07, was completely sequenced. No unexpected changes other than common polymorphisms in the genes within the MDR were found (see supplementary data in Supplemental Table C ).
Hemizygous loss of TRAIL receptor genes results in down regulation of cell surface expression of TRAIL receptor proteins.
To determine if chromosome 8p deletion affected gene expression across the genomic region at 8p we assessed gene expression using the Lymphochip cDNA microarray. Among 79 genes/ESTs that mapped to 8p in the Lymphochip microarray, only five (6%) showed statistically significant down-regulation in cell lines with 8p loss with respect to those with both alleles intact (Figure 2A) . Notably, only two of these down-regulated cDNAs mapped into the critical region at Figure 2D ).
Sensitivity to TRAIL-induced apoptosis is dependent on TRAIL-R1 and TRAIL-R2 gene and protein dosage.
Regulation and maintenance of expression of death and decoy receptors is critical for controlling apoptosis. 33, 37, 38 Examination of TRAIL-induced apoptotic response in the lymphoma cell lines after exposure to different TRAIL doses revealed that TRAIL-mediated apoptosis was directly related to TRAIL-R1 and TRAIL-R2 expression in most tumors, but not to that of TRAIL-R3/TRAIL-R4 ( Figure 3A ). Resistance to apoptosis was higher in cell lines with 8p deletion vs.
non-deleted strains: 7 of 9 (78%) vs. 2 of 8 (25%) of tumors showed <25% cell apoptosis after 24-h incubation with 500 ng of TRAIL, respectively. The Z138 cell line, which exhibits deletion of TRAIL-R2 and showed TRAIL-R1 to be mapped at the centromeric border of the deletion in 8p21.3, was sensitive to TRAIL-induced apoptosis; expression levels of the receptors were higher for TRAIL-R1 than for TRAIL-R2, suggesting that in Z138 cells the TRAIL-induced sensitivity may be mediated via TRAIL-R1 signaling. In the MD901 cell line, which shows deletion of both TRAIL-R1 and TRAIL-R2 genes and is sensitive to TRAIL-induced apoptosis, expression of TRAIL-R1 was very low but TRAIL-R2 was expressed at higher levels, perhaps indicating signaling through TRAIL-R2 receptor. Because polymorphisms in the untranslated regions of TRAIL receptor 39 we checked whether a 3´UTR region of TRAIL-R2 as well as other known and novel polymorphisms observed in the TRAIL receptors correlated with the levels of expression of the receptors and/or the resistance to TRAIL-induced apoptosis. None of the polymorphisms was associated with differences in expression or sensitivity to TRAIL-induced apoptosis (Table 1) . To investigate whether P53 gene, which directly binds to TRAIL-R2 promoter and signals apoptotic death, 40 carried mutations that may have influenced in the TRAIL sensitivity, we screened for P53 mutations. Inactivating mutations were observed in one of the sensitive cell lines (MD901) but also in resistant strains (Namalwa), excluding correlation with TRAIL-R1/TRAIL-R2 expression or with TRAIL-mediated apoptosis.
Restoration of TRAIL-R1 and TRAIL-R2 expression reversed resistance to TRAIL-mediated apoptosis
In search for a model, we evaluated whether variation in TRAIL-R1 and/or TRAIL-R2 expression levels after gene transfection enhanced TRAIL-induced apoptosis in B-cells. FLAG-tagged TRAIL-R1 and TRAIL-R2 expression constructs were transfected alone and co-transfected simultaneously, into five lymphoma cell lines with 8p loss (Namalwa, SUDHL6, REC1, JVM2 and NCEB1). We only obtained stable transfections of TRAIL-R2 in Namalwa cells, derived from Burkitt lymphoma, and of TRAIL-R1 in SUDHL6 cell line, derived from diffuse large B cell lymphoma with t(14;18)(q32;q21). Both cell lines showed deletion of 8p21.3 including TRAIL-R1
and TRAIL-R2 gene loci and were resistant to TRAIL-induced apoptosis. In both, expression of TRAIL-R1 and R2 was increased by less than two fold, resembling the expression levels of most cell lines with two 8p21.3 alleles. Increased TRAIL-R2 expression in Namalwa cells and TRAIL-R1 expression in SUDHL6 were both associated with restoration of TRAIL-induced sensitivity, whereas non-transfected cell lines used as controls remained resistant (Figure 3 B) . These data For personal use only. at PENN STATE UNIVERSITY on March 1, 2013. bloodjournal.hematologylibrary.org From indicated that the extrinsic apoptotic pathway was not structurally damaged in these two cell lines and that TRAIL-induced apoptosis was reversible with expression of the receptors, depending on TRAIL-R1 and TRAIL-R2 protein dosage. Therefore, TRAIL-R1 and TRAIL-R2 seem to show a gene-dosage effect that can be disrupted by chromosome deletion, thus impairing TRAIL-induced apoptosis in B-cells.
For
DISCUSSION
Genetic analysis has suggested that deletion of sequences that map to chromosome 8p may be critical for tumorigenesis in epithelial carcinomas as well as in hematological malignancies. 21 However, a marked heterogeneity in the different publications has led to the description of several critical regions of deletion in 8p. Here, we delineate a MDR in chromosome 8p21.3 that is coincident with some of the reported deletions in other tumors. Among the previous reports, Hamaguchi et al. 15 used representational difference analysis to narrow down a region of homozygous deletion in breast cancer overlapping with ours that contained TRAIL-R2 but not
TRAIL-R1 whereas Swalwell et al. analyzed microsatellite markers for LOH in prostate tumors
and delineated a MDR of 1.5 Mb in 8p21.3 including the four TRAIL receptor genes. 41 In two additional publications using microsatellite analysis, common regions of deletions spanning 8p21.3 were identified in non-small lung and colorectal carcinomas. 42, 43 With the combination of high-resolution array CGH and FISH mapping, we defined the MDR to 600 kb in 8p21.3 that may harbor one or more tumor suppressor gene/s involved not only in B-cell lymphoma, but also in other cancer types.
Monoallelic deletion with concurrent mutation of the remaining allele and/or promoter methylation is a common mechanism of inactivation for tumor suppressor genes. Among the genes located within the MDR, the TRAIL receptor genes were selected initially based on their roles in signaling apoptosis and because mutations of TRAIL-R1 and TRAIL-R2 had been reported in lymphoma and in other cancers. 34, 35 However, we failed to identify any pathogenic mutation or promoter methylation in TRAIL-R1 and TRAIL-R2... In addition, obvious pathogenic mutations were excluded in the candidate tumor suppressor DBC2, contained within the MDR, and in the PPP3C gene, located at the telomeric border of the MRD. Sequencing of the entire interval of MDR in the Z138 cell line failed to identify sequence changes in all the genes within the MDR as well.
For personal use only. at PENN STATE UNIVERSITY on March 1, 2013. bloodjournal.hematologylibrary.org From Notably, the gene encoding the decoy receptor TRAIL-R3 showed frequent hemizygous loss plus silencing of the second allele by promoter methylation, therefore fulfilling the criteria for "two-hit" TSGs. However, this decoy receptor does not contain a functional domain, and seems to block TRAIL-induced apoptosis by competing with TRAIL-R1 and TRAIL-R2. 33, 37 Therefore, this gene may not be considered a tumor suppressor gene a priori, but we cannot exclude that TRAIL-R3 could have unreported functions besides its role as decoy receptor and might be implicated in the lymphoma pathogenesis. It should be noted that within the MDR described here there are no identified micro-RNA genes. 20 . Also in agreement with these data, several reports indicate that TRAIL can induce rejection or apoptosis of tumor cells. [44] [45] [46] [47] [48] Cretney et al. reported that TRAIL knock-out mice were more susceptible to experimental and spontaneous tumor metastasis whereas 48 Takeda et al. found that development of spontaneous tumors in p53 +/-mice was promoted by neutralization of TRAIL. 46 (TRAIL-R) deficient mice (mDR5, mTRAILR2, or mKILLER), the only full-length TRAIL receptor in mouse with equal homology to human TRAIL-R1 and TRAIL-R2. Mice were born at the expected Mendelian ratios and showed no developmental abnormalities. The authors defined a role for TRAIL-R signaling independent of its ability to initiate apoptosis in sensitive cells. 49 Remarkably, these animals did not develop tumors spontaneously. More importantly, crossing of the TRAIL-Rdeficient mice with p53 -/-mice and with Apc MIN/+ mice, two well established models of tumorigenesis, did not affect the onset or growth of T-cell thymomas and intestinal tumors, respectively. 50 The role of TRAIL-R deficiency was not evaluated, however, in a B-cell lymphoma mouse model, and thus cannot be fully compared with our results. Finnberg et al. created another knock-out mouse lacking TRAIL-R. 51 This mouse was viable and developed normally with the exception of enlarged thymus. Authors showed that loss of TRAIL-R diminished apoptosis in immortalized cells. In addition, they showed that TRAIL-R plays a role in the DNA damage response of the immune cells of the thymus and of the spleen and in particular in the lymphocytes of the white pulp. These data may help to interpret our results, as we can hypothesize that TRAIL-R1/R2 show different function in B-cell lymphocytes, including modulation of TRAILinduced apoptosis. Consequently, TRAIL-R1 and/or TRAIL-R2 might show tumor suppressor activity in B-cell lymphoma, as we have initially shown in this manuscript. We may also speculate on different roles of TRAIL receptors in humans compared to mice, which only bears one TRAIL receptor instead of the two observed in humans and primates. 52 Further experimental studies will clarify whether TRAIL-R deficiency may enhance tumor formation in well-characterized B-cell lymphoma mouse models.
In summary, we have delineated a novel MDR in chromosome 8p21.3 and have provided data that suggest that TRAIL-R1 and TRAIL-R2 genes are the targets of the deletion. These genes 
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